J P Morgan Chase & Co reaffirmed their buy rating on shares of Incyte Corporation (NASDAQ:INCY) in a research report report published on Thursday. The brokerage currently has a $149.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on INCY. BidaskClub downgraded shares of Incyte Corporation from a buy rating to a hold rating in a research report on Friday, August 4th. Evercore ISI began coverage on shares of Incyte Corporation in a research report on Wednesday, August 16th. They issued an in-line rating and a $135.00 price target for the company. Credit Suisse Group reiterated a buy rating on shares of Incyte Corporation in a research report on Saturday, June 10th. Cowen and Company reiterated an outperform rating and issued a $130.00 price target on shares of Incyte Corporation in a research report on Monday, July 3rd. Finally, Barclays PLC reiterated an overweight rating and issued a $165.00 price target (down from $180.00) on shares of Incyte Corporation in a research report on Wednesday, August 2nd. Eight research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $140.16.

Incyte Corporation (NASDAQ INCY) opened at 138.03 on Thursday. The firm’s market capitalization is $28.39 billion. The stock has a 50 day moving average price of $129.15 and a 200-day moving average price of $130.00. Incyte Corporation has a one year low of $77.58 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.01. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The business had revenue of $326.40 million during the quarter, compared to analyst estimates of $318.45 million. During the same quarter in the previous year, the firm posted $0.18 earnings per share. The firm’s quarterly revenue was up 32.5% on a year-over-year basis. On average, equities analysts forecast that Incyte Corporation will post ($0.86) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Incyte Corporation’s (INCY) Buy Rating Reaffirmed at J P Morgan Chase & Co” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/04/incyte-corporations-incy-buy-rating-reaffirmed-at-j-p-morgan-chase-co.html.

In other Incyte Corporation news, CFO David W. Gryska sold 16,756 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $116.60, for a total transaction of $1,953,749.60. Following the sale, the chief financial officer now owns 35,771 shares of the company’s stock, valued at $4,170,898.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Steven H. Stein sold 2,111 shares of the business’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $125.00, for a total transaction of $263,875.00. Following the sale, the executive vice president now directly owns 18,687 shares in the company, valued at approximately $2,335,875. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,474 shares of company stock worth $5,606,721. Insiders own 17.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. D. Scott Neal Inc. bought a new stake in shares of Incyte Corporation in the second quarter worth $103,000. Tower Research Capital LLC TRC bought a new stake in shares of Incyte Corporation in the first quarter worth $105,000. Cornerstone Advisors Inc. grew its stake in shares of Incyte Corporation by 19.6% in the second quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 145 shares during the last quarter. Exane Asset Management bought a new stake in shares of Incyte Corporation in the second quarter worth $126,000. Finally, Seven Eight Capital LP bought a new stake in shares of Incyte Corporation in the second quarter worth $129,000. 91.06% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.